CAIX-Targeted PET Detects Nearly All Clear-Cell Kidney Cancer Lesions
Presented at the 39th EANM Congress in October 2026, the tracer outperformed 18F-FDG, changed staging or treatment plans in about 31% of patients, requiring larger subtype‑stratified trials to prove outcome benefit.
